Yuhan Corporation and Novartis Korea Sign Strategic Partnership for "Rapcido"

Distribution and Promotion of Chronic Spontaneous Urticaria Treatment

"We Will Do Our Best to Improve the Treatment Environment"

Yuhan Corporation announced on September 7 that it has signed a strategic partnership agreement with Novartis Korea for the domestic distribution, sales, and promotion of "Rapcido" (active ingredient: Remibrutinib), the first oral BTK inhibitor in the field of chronic spontaneous urticaria treatment.

Under this partnership, Yuhan Corporation will be exclusively responsible for the domestic distribution of Rapcido. Promotional activities for general hospitals will be conducted by Novartis Korea, while promotional activities for clinics will be undertaken by Yuhan Corporation.

Yuhan Corporation announced on the 7th that it has signed a strategic partnership agreement with Novartis Korea for the domestic distribution, sales, and promotion of Lapsido (active ingredient Remibrutinib). Byungjae Yoo, CEO of Novartis Korea (left), and Wookje Cho, CEO of Yuhan Corporation, are taking a commemorative photo. Yuhan Corporation

Rapcido is an oral inhibitor targeting BTK2 and was approved in Korea in April as a treatment for adult patients with chronic spontaneous urticaria (CSU) who are inadequately controlled with H1 antihistamines. Chronic spontaneous urticaria is a disease in which, during the activation of mast cells, inflammatory mediators such as histamine cause symptoms including wheals, angioedema, and itching.

The two companies plan to engage in various activities to improve access to treatment for patients who need Rapcido and to raise awareness of chronic spontaneous urticaria as a disease.

Jo Wookje, CEO of Yuhan Corporation, stated, "Based on our strong sales and marketing capabilities and extensive nationwide distribution network, we will do our utmost to effectively convey the value of Rapcido to healthcare professionals and patients, and to contribute to improving the treatment environment."

Yoo Byungjae, CEO of Novartis Korea, commented, "We look forward to providing more patients with new treatment opportunities and contributing to the advancement of the treatment environment for chronic spontaneous urticaria in Korea, leveraging the expertise and capabilities of both companies."

This content was produced with the assistance of AI translation services.